NasdaqGM:SGMTBiotechs
Assessing Sagimet Biosciences (SGMT) Valuation After Positive Denifanstat Phase 3 Acne Trial Results
Sagimet Biosciences (SGMT) is back on investors’ radar after partner Ascletis Pharma reported that Denifanstat, also known as ASC40, met all primary and secondary endpoints in a Phase 3 acne trial.
See our latest analysis for Sagimet Biosciences.
Despite the positive Phase 3 acne data, Sagimet’s 1 day share price return was a 7.32% decline to US$6.08. Its 30 day share price return of 9.75% contrasts with a 20.94% decline over 90 days and a 1 year total shareholder return of 18.52%, suggesting...